Protalix BioTherapeutics (DE) (PLX) vs Sutro Biopharma (STRO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 7, 2026.
Summary
Sutro Biopharma (STRO) has outperformed Protalix BioTherapeutics (DE) (PLX) over the past year, gaining 74.5% versus a gain of 8.4%. Over five years, PLX leads with a +120.3% price change compared with -92.3% for STRO. Sutro Biopharma is the larger company by market cap ($243.1 million vs $218.3 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PLX | STRO |
|---|---|---|
| Share price | $2.71 | $14.66 |
| Market cap | $218.35M | $243.08M |
| 1-day change | -0.73% | +1.45% |
| YTD return | +50.56% | +26.71% |
| 1-year return | +8.40% | +74.52% |
| 5-year return | +120.33% | -92.28% |
| P/E ratio (TTM) | 11.78 | — |
| Forward P/E | 4.37 | — |
| EPS (TTM) | $0.23 | $-17.28 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.19 | $43.85 |
| 52-week low | $1.60 | $7.15 |
| Distance from 52-week high | -15.05% | -66.57% |
| Average volume | 729.36K | 289.73K |
| Shares outstanding | 80.57M | 16.58M |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- STRO has outperformed PLX by 66.1 percentage points over the past year.
PLX vs STRO FAQ
Which is bigger, Protalix BioTherapeutics (DE) or Sutro Biopharma?
Sutro Biopharma (STRO) is larger, with a market capitalization of $243.08M compared with $218.35M for Protalix BioTherapeutics (DE) (PLX).
Which stock has performed better over the past year, PLX or STRO?
STRO returned +74.52% over the past 12 months, compared with +8.40% for PLX (price return, excluding dividends). Past performance does not predict future results.
Are Protalix BioTherapeutics (DE) and Sutro Biopharma in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.